...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The journal of clinical psychiatry >Long-term maintenance therapy with quetiapine versus haloperidol decanoate in patients with schizophrenia or schizoaffective disorder.
【24h】

Long-term maintenance therapy with quetiapine versus haloperidol decanoate in patients with schizophrenia or schizoaffective disorder.

机译：喹硫平与癸酸氟哌啶醇对精神分裂症或精神分裂症患者的长期维持治疗。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

OBJECTIVE: To compare the long-term efficacy and tolerability of oral quetiapine with those of intramuscular haloperidol. METHOD: Patients with DSM-IV-diagnosed schizophrenia or schizoaffective disorder requiring long-term antipsychotic treatment were randomly assigned to open-label oral quetiapine or intramuscular haloperidol decanoate for 48 weeks. Clinicians were instructed to target dosing at 500 mg/day of quetiapine or 200 mg of haloperidol decanoate every 4 weeks. The Positive and Negative Syndrome Scale was used to assess efficacy; the Simpson-Angus Scale and the Barnes Akathisia Scale were used to assess safety and tolerability. For statistical analyses, a general linear mixed-model repeated-measures analysis of covariance was used, with change scores for dependent variables computed with the baseline score as covariate. Data were collected from 1998 to 2001. RESULTS: Thirty-five patients were enrolled, but 6 did not participate after being informed of their treatment assignment; 4 of the 6 withdrawals were assigned to haloperidol decanoate. Mean doses at week 48 were 493 mg/day of quetiapine (N = 16) and 170 mg/28 days of haloperidol decanoate (N = 9). Survival analysis showed no between-group differences in estimates of the number of patients remaining exacerbation-free over time. Both drugs were efficacious, but quetiapine was significantly better than haloperidol decanoate in controlling negative symptoms (p < .05). The incidence of extrapyramidal symptoms was low in both groups; patients receiving quetiapine showed significantly greater improvement in rigidity and akathisia (p < .05). CONCLUSION: Oral quetiapine was as efficacious as intramuscular haloperidol in preventing symptom exacerbation over 48 weeks in patients with schizophrenia or schizoaffective disorder, with fewer extrapyramidal symptoms, especially rigidity and akathisia. Quetiapine was more efficacious than haloperidol decanoate in treating negative symptoms.
机译：目的：比较口服喹硫平与肌注氟哌啶醇的长期疗效和耐受性。方法：将需要长期抗精神病治疗且经DSM-IV诊断为精神分裂症或精神分裂症的患者随机分配至开放标签的口服喹硫平或肌注氟哌啶醇癸酸酯48周。指示临床医生以每4周每日500毫克的喹硫平或200毫克氟哌啶醇癸酸酯的剂量为目标。阳性和阴性综合征量表用于评估疗效。 Simpson-Angus量表和Barnes Akathisia量表用于评估安全性和耐受性。对于统计分析，使用了协方差的一般线性混合模型重复测量分析，其中因变量的变化得分以基线得分为协变量来计算。结果：收集了1998年至2001年的数据。结果：招募了35例患者，但有6例患者在得知其治疗分配后未参加研究。 6份撤药中有4份被分配给氟哌啶醇癸酸酯。第48周的平均剂量为493毫克/天的喹硫平（N = 16）和170毫克/ 28天的氟哌啶醇癸酸酯（N = 9）。生存分析显示，随着时间的流逝，无恶化的患者数量的估计没有组间差异。两种药物均有效，但喹硫平在控制阴性症状方面明显优于氟哌啶醇癸酸酯（p <.05）。两组锥体外系症状的发生率均较低。接受喹硫平的患者在僵硬和静坐无力方面表现出明显更大的改善（p <.05）。结论：口服喹硫平在预防精神分裂症或精神分裂症患者超过48周的症状加重方面与肌注氟哌啶醇一样有效，且锥体外系症状较少，特别是僵硬和静坐无力。喹硫平在治疗阴性症状方面比氟哌啶醇癸酸酯更有效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号